Finally, similar to GLP-1 RAs, the medication should not be used in patients with a history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) [31, 43]. This evidence concerns the gene GLP1R and medullary thyroid gland carcinoma.